skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

19 Total results for product and free and sample content found

Pink Sheet: 世界の薬事規制と承認審査に関するニュース

Regeneron Pushes Legal, Ethical Boundaries With Offer Of COVID-19 Antibody To Biden Campaign

Company may have violated FDA’s preapproval promotion restrictions by discussing compassionate use option with Joe Biden’s team and by publicizing it on TV, highlighting the fine line between making the general public aware of expanded access and touting an investigational product as useful for a particular illness.

Topic Coronavirus Advertising Marketing Sales us-election-2020

Pink Sheet: 世界の薬事規制と承認審査に関するニュース, Scrip: 世界の医...

Executive Privilege: How Giving Trump Special Access To Experimental COVID Treatment Could Backfire

Trump receives Regeneron’s experimental antibody under FDA’s expanded access program, Gilead’s remdesivir and dexamethasone. The president’s treatment choices could influence clinical trials of all COVID-19 medicines and even trial recruitment for other diseases, experts said.

Topic Coronavirus us-election-2020 clinical-trials

Pink Sheet: 世界の薬事規制と承認審査に関するニュース

US Election 2020: Trump's Sway Over Courts Expected To Linger

Textualist judges appointed by President Trump during his term may block a potential President Biden’s attempts to shift the government’s legal policies.

Topic us-election-2020 policy-and-regulation

Pink Sheet: 世界の薬事規制と承認審査に関するニュース

VP Debate: Pence Tries Vaccine Hesitancy Jujutsu On Harris

Harris Pence VP Debate

‘Senator, please stop undermining confidence in a vaccine,’ Pence says when confronted with the accusation that the administration is politicizing the COVID vaccine development effort.

Topic Coronavirus vaccines us-election-2020

Pink Sheet: 世界の薬事規制と承認審査に関するニュース

'Like Water': Pharma Avoids Much Scrutiny In Messy Presidential Debate

Trump and Biden trade barbs in debate that included a suggestion by the president that coronavirus vaccine development delays are political and saw Biden questioned on whether he was contributing to vaccine hesitancy.

Topic US Election 2020 Drug Pricing Policy & Regulation

Generics Bulletin: ジェネリック&バイオシミラーニュース

AAM Ramps Up US Election Lobbying

The AAM has published a timely guide highlighting various voter issues of concern in the run-up to the US elections, including anti-competitive tactics building on monopoly pricing and weak patent laws. The AAM has also called for policies to encourage generic and biosimilar entry in the market while the guide also focuses on policies around the US supply chain.

Topic US Election 2020 Policy & Regulation

Pink Sheet: 世界の薬事規制と承認審査に関するニュース

Six Pharma CEOs To Testify In House as Democrats, Trump Compete For Attention On Drug Pricing

US Election Drug Pricing Debate

While neither party is likely to make any big policy changes this year, the action from both sides of the aisle indicates politicians still see going after pharma as a winning issue with voters even as polls show voters are focused elsewhere.

Topic us-election-2020 drug-pricing

Pink Sheet: 世界の薬事規制と承認審査に関するニュース

'March In' Plan Unveiled By Democratic Think Tank: A Battle Biopharma Would Welcome?

In sign of how much has changed in four years, industry might be better off if Biden takes CAP’s advice and launches ‘march-in’ actions to address pricing of COVID products.

Topic us-election-2020 drug-pricing

Pink Sheet: 世界の薬事規制と承認審査に関するニュース

Biden's Drug Pricing Administrative Actions Could Focus On Medicare Demos

Center for American Progress suggests pricing reforms for the 'next Administration' in lieu of legislation.

Topic us-election-2020 drug-pricing

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。